- Market Realist•2 hours ago
Sanofi’s (SNY) established prescription products contributed nearly 28.9% of the company's total 4Q16 revenues.
- Motley Fool•yesterday
A big phase 3 win for its up-and-coming multiple sclerosis drug could clear the path to billions of dollars in additional annual sales for this big-cap biotech stock.
- Market Realist•3 days ago
Sanofi reported a sequential revenue growth of ~3.4% at constant exchange rates for 4Q16.
SAN.PA : Summary for SANOFI - Yahoo Finance
Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
|Bid||71.12 x 1000|
|Ask||71.74 x 44000|
|Day's Range||80.19 - 81.96|
|52 Week Range||62.50 - 82.45|
|PE Ratio (TTM)||22.01|
|Dividend & Yield||3.35 (3.91%)|
|1y Target Est||N/A|